Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway

Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and nivolumab, act through blockade of the PD-1–PDL-1 interaction. Here, we have identified novel antagonistic anti–PD-1 Abs not blocking the PD-1–PDL-1 interaction. The nonblocking Abs recognize epitopes on PD-1 located o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenwick, Craig, Loredo-Varela, Juan-Luis, Joo, Victor, Pellaton, Céline, Farina, Alex, Rajah, Navina, Esteves-Leuenberger, Line, Decaillon, Thibaut, Suffiotti, Madeleine, Noto, Alessandra, Ohmiti, Khalid, Gottardo, Raphael, Weissenhorn, Winfried, Pantaleo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605749/
https://www.ncbi.nlm.nih.gov/pubmed/31123083
http://dx.doi.org/10.1084/jem.20182359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605749/
https://www.ncbi.nlm.nih.gov/pubmed/31123083
http://dx.doi.org/10.1084/jem.20182359

Ejemplares similares